Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study

BACKGROUND: Despite the intense global research endeavour to improve the treatment of patients with COVID-19, the current therapy remains insufficient, resulting in persisting high mortality. Severe cases are characterised by a systemic inflammatory reaction driven by the release of pro-inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Coldewey, Sina M., Neu, Charles, Bloos, Frank, Baumbach, Philipp, Schumacher, Ulrike, Bauer, Michael, Reuken, Philipp, Stallmach, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438250/
https://www.ncbi.nlm.nih.gov/pubmed/36056419
http://dx.doi.org/10.1186/s13063-022-06566-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438250/
https://www.ncbi.nlm.nih.gov/pubmed/36056419
http://dx.doi.org/10.1186/s13063-022-06566-5

Ejemplares similares